

Supplementary Table 3. Characteristics of the patients without treatments

	ACA (n=91)	SCL70 (n=36)	
Age – years [IQR] – (N)	59 [52-69] (91)	55 [44-68] (36)	p=0.14
Female Sex – % – (n/N)	93 (85/91)	83 (30/36)	
Disease duration – years [IQR] – (N)	11.3 [4.6-15]	10.3 [3.25-14.7]	p=0.41
Diffuse cutaneous systemic sclerosis – % – (n/N)	1.9 (1/54)	59 (17/29)	p<0.0001
Cigarette smoking – % – (n/N)	14 (12/84)	9 (3/35)	p=0.55
Gastroesophageal reflux – % – (n/N)	67 (60/90)	69 (25/36)	p=0.83
Esophageal dysmotility – % – (n/N)	60 (43/72)	61 (19/31)	p=1
Pulmonary hypertension – % – (n/N)	13 (11/82)	15 (5/33)	p=0.77
Basilar crackles – % – (n/N)	8 (7/91)	36 (13/36)	p=0.0002
Ventilatory restriction – % – (n/N)	15 (12/79)	42 (14/33)	p=0.003
Pulmonary fibrosis – % – (n/N)	16 (12/77)	50 (17/34)	p=0.0003
Worsening lung function – % – (n/N)	9 (7/76)	18 (6/33)	p=0.20
Inflammatory myopathy – % – (n/N)	0 (0/78)	3 (1/33)	p=0.30
Active Arthritis – % – (n/N)	11 (10/90)	25 (9/36)	p=0.058
Raynaud phenomenon – % – (n/N)	95 (87/91)	100 (36/36)	p=0.58
Calcinosis cutis – % – (n/N)	24 (21/88)	21 (7/34)	p=0.81
Skin fibrosis – % – (n/N)	60 (54/90)	80 (29/36)	p=0.04
Presence of ischemic digital ulcers or pitting scars – % – (n/N)	16 (15/91)	44 (15/34)	p=0.002
Puffy fingers – % – (n/N)	4 (4/90)	11 (4/35)	p=0.22
Inflammation (ESR>30mm or abnormal CRP 4 weeks before inclusion) – % – (n/N)	23 (20/89)	31 (11/36)	p=0.025

(n/N): number of patients / Total number of patients with available data.